Please assess the completion status of the following clinical trial:

Trial Title: Effect of Serum LDL Cholesterol Concentration on Pancreatic Insulin Secretion

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures~* Medical indication for the treatment with a PCSK9-inhibitor~* HbA1c \< 6,5%~Exclusion Criteria:~* Diabetes mellitus~* Pregnant women or breastfeeding~* Hb \< 11.5 g/dl (males) or Hb \< 10.5 g/dl (females)~* treatment with any medication that effects on blood glucose concentrations, e.g. antidiabetic drugs or steroids~* Any pancreatic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- LDL lowering therapy (Type: EXPERIMENTAL): Patients will receive the PCSK9-inhibitor Evolocumab as part of routine clinical management within the indication of this drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).